Abstract:Objective To investigate mutation status of isocitrate dehydrogenase (IDH) 1 and IDH2 genes in Chinese patients with gliomas in correlation with clinicopathological characteristics.Methods Formalin-fixed and paraffin-embedded (FFPE) tissue samples of 234 gliomas were collected including the matched blood samples in 30 patients.DNA was extracted,followed by PCR-Sanger sequencing to detect IDH1 and IDH2 gene mutations.Immunohistochemistry was performed using mutation-specific antibody recognizing IDH1R132H mutation.Immunostains for p53 and epidermal growth factor receptor (EGFR) were also performed.Oligodendroglial tumors with IDH mutation were double stained with IDH1R132H and GFAP by immunofluorescence to investigate the location of IDH1 R132H expression.Results (1) By IDH1 heterozygous somatic mutation analysis,Arg132His (c:G395A) was found in 31.6％ (74 of 234) of the cases.IDH mutations were more frequent in oligoastrocytomas (9/13),anaplastic oligoastrocytomas (7/11),oligodendrogliomas (18/26,69.2％),anaplastic oligodendrogliomas (8/10),and less frequent in diffuse astrocytomas (17/47,36.2％),anaplastic astrocytomas (5/18),and glioblastomas (10/69,14.5％).The mutation rate inversely correlated with the tumor grade in a linear fashion in astrocytic tumors (P =0.007).Primary glioblastomas were characterized by a lower frequency of mutations than secondary glioblastomas (5/55 vs.5/14,P =0.036); IDH mutation was not detected in pilocytic astrocytoma and ependymoma.No IDH2 mutation was identified in this study cohort.(2) Immunohistochemistry of IDH1R132H demonstrated a strong cytoplasmic staining in 80 cases,which was highly correlated with IDH mutation status (P =0.001).IDH1R132H was highly specific to tumor cells.(3) p53 immunostain was significantly correlated the IDH mutation in diffuse astrocytoma,anaplastic astrocytoma and secondary glioblastomas (P =0.007,0.026,0.038 respectively).(4) No correlation between EGFR and IDH mutation was found.Conclusions High prevalence of IDH heterozygous somatic mutation occurs in the earlier stage of gliomas,which can be detected by mutation-specific antibody IDH1R132H.Furthermore,evaluation of p53 and EGFR expression combined with IDH mutation analysis may significantly aid in the diagnosis and differential diagnoses of gliomas in Chinese patients.

Analysis of the P21 Gene in Gliomas

Expressions of p57kip2 and p21cip1 in human glioma and their clinical significance

p21: A Two-Faced Genome Guardian

Germline Mutations of P53 but Not P16/Cdkn2 or Pten/Mmac1 Tumor Suppressor Genes Predispose to Gliomas

Correlation Analysis Between the Expression of P21WAF1/CIP1, P16 Proteins and Human Glioma

Mutational Analysis of the PTEN Gene in Gliomas: Molecular and Pathological Correlations

Expression analysis of human glioma susceptibility gene and P53 in human glioma and its clinical significance based on bioinformatics

The p21 cyclin–dependent kinase inhibitor suppresses tumorigenicity in vivo

Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation

[Expression and Clinical Significance of P53 Protein and P21(waf1) in Non-Small-cell Lung Carcinoma].

Expression of CyclinD1/Bcl-1 and p27/Kip1 in Gliomas:Their Correlation with Pathological Grade and Prognosis

Expressions and Clinical Significance of MDM2, P53 and P21waf1 Proteins in Gliomas Tissues

Apoptosis of Human Gastric Cancer Cell Line SGC-7901 by P21 Gene Transduction

Detection of Expression of P21 Gene in Neuroblastoma

Differential Expression of P42.3 in Low- and High-Grade Gliomas

MDM2,p53,p14~(ARF) and P21~(waf1) Protein Expression in Gliomas and Its Significance

Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma

The Relationship Between P53 Gene Mutations and Clinicopathological Features in Glioma

Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma.

p21 expression in gestational trophoblastic disease: correlation with clinicopathological parameters, and Ki67 and p53 gene expression

The role of p16 gene mutation in human brain glioma tumorigenesis